<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">2223581</article-id><article-id pub-id-type="pmc">1971477</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Moseley</surname><given-names>R. P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>A. G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>R. B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zalutsky</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Carrell</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fabre</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Slack</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bullimore</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pizer</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Papanastassiou</surname><given-names>V.</given-names></name></contrib><etal/></contrib-group><aff>Department of Neurosurgery, Frenchay Hospital, Bristol, UK.</aff><pub-date pub-type="ppub"><month>10</month><year>1990</year></pub-date><volume>62</volume><issue>4</issue><fpage>637</fpage><lpage>642</lpage><abstract><p>Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00218-0089.tif" xlink:title="scanned-page" xlink:role="637" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00218-0090.tif" xlink:title="scanned-page" xlink:role="638" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00218-0091.tif" xlink:title="scanned-page" xlink:role="639" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00218-0092.tif" xlink:title="scanned-page" xlink:role="640" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00218-0093.tif" xlink:title="scanned-page" xlink:role="641" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00218-0094.tif" xlink:title="scanned-page" xlink:role="642" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

